• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP CA 19-9 ASSAY IMMUNOLOGICAL TEST FOR CA 19-9 ANTIGEN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP CA 19-9 ASSAY IMMUNOLOGICAL TEST FOR CA 19-9 ANTIGEN Back to Search Results
Model Number N/A
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 11/18/2016
Event Type  malfunction  
Manufacturer Narrative
The cause for the discordant advia centaur xp ca19-9 results with the alternate method is unknown. Siemens healthcare diagnostics is investigating. The instrument is performing within specifications. The ifu states in the interpretation of results section: "results of this assay should always be interpreted in conjunction with patient's medical history, clinical presentation and other findings. " the ifu states in the limitations section: "warning do not use the advia centaur ca 19-9 assay as a screening test or for diagnosis. Do not predict disease recurrence solely on levels of advia centaur ca 19-9. Normal levels of advia centaur ca 19-9 do not always preclude the presence of disease. Note: do not interpret serum levels of ca 19-9 as absolute evidence of the presence or the absence of malignant disease. Before treatment, patients with confirmed gi carcinoma frequently have levels of ca 19-9 within the range observed in healthy individuals. Additionally, elevated levels of ca 19-9 can be observed in patients with nonmalignant diseases. Measurements of ca 19-9 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation. The concentration of ca 19-9 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity. Ca 19-9 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity. Therefore, it is important to use assay specific values to evaluate quality control results. ".
 
Event Description
A false high advia centaur xp ca 19-9 result was obtained for a patient sample. The ultrasound and other diagnosis for the patient were normal. The patient sample was tested at another laboratory on the advia centaur xp and the result was high. The patient sample was diluted and the results were high. The patient sample was tested on two alternate methods and the results were normal. A corrected report was issued. Patient treatment was not prescribed or altered. There was no report of adverse health consequences due to the discordant ca 19-9 results.
 
Manufacturer Narrative
Siemens filed the initial mdr 1219913-2016-00253 on december 20, 2016. On 12/27/2016 additional information: the type of blood collection tube is being used is becton dickinson (bd) serum separator tube (sst) ii. The customer tested the sample with ca 19-9 lot 388 on (b)(6) 2016 and the ca 19-9 data was 173. 88 u/ml. The first time the customer tested the sample ca 19-9 was (b)(6) 2016. The customer did not use a heterophilic blocking tube (hbt). When the customer diluted the sample, it did not dilute linearly indicating something in the sample might be interfering with the advia centaur xp ca 19-9 assay. The customer did not try treating the sample with a heterophilic blocking tube (hbt) and there is not sufficient sample left to investigate further. The cause for the discordant advia centaur xp ca19-9 results is unknown. The difference in results between the advia centaur xp ca19-9 assay and the alternate methods is most likely due to some unknown interferent. The instrument is performing within specifications. No further evaluation of the device is required.
 
Manufacturer Narrative
Siemens filed the initial mdr 1219913-2016-00253 on december 20, 2016. Siemens filed the mdr 1219913-2016-00253 supplemental report 1 on january 5, 2017. On 02/09/2017 correction: the correct date for the "date received by the manufacturer" is 11/23/2016. On 02/09/2017 additional information: (b)(6).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameADVIA CENTAUR XP CA 19-9 ASSAY
Type of DeviceIMMUNOLOGICAL TEST FOR CA 19-9 ANTIGEN
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
511 benedict avenue
tarrytown NY 10591 5097
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
333 coney street
e. walpole MA 02032
Manufacturer Contact
eiman sulieman
333 coney street
e. walpole, MA 02032
5086604603
MDR Report Key6188817
MDR Text Key62858061
Report Number1219913-2016-00253
Device Sequence Number1
Product Code NIG
Combination Product (y/n)N
Reporter Country CodeTW
PMA/PMN Number
K031393
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,u
Reporter Occupation Other Health Care Professional
Remedial Action Inspection
Type of Report Initial,Followup,Followup
Report Date 02/23/2017
1 Device was Involved in the Event
0 Patients were Involved in the Event:
Date FDA Received12/20/2016
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator
Device Expiration Date03/24/2017
Device Model NumberN/A
Device Catalogue Number10491379
Device Lot Number33018386
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received02/09/2017
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

-
-